Prostate Cancer Incidence and Mortality Have Declined in Most Countries
ATLANTA – Prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world, with...
Search/Filter
Loading...
HDAC Inhibition May Combat Resistance to Anti-PD-1 Therapy in Patients With Melanoma
ATLANTA – A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed...
Next-generation TRK-targeted Therapeutic, LOXO-195, Shows Early Promise Against Tumors with Acquired Resistance to First-generation Therapeutics
ATLANTA – The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called...
Data From Two KEYNOTE Trials Show Pembrolizumab Benefited Patients With Advanced Small Cell Lung Cancer
ATLANTA – The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated,...
Umbralisib Shows Early Promise for Patients with Marginal Zone Lymphoma
ATLANTA – The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients...
Cancer Preventive Vaccine Showed Promising Results in Preclinical Model of Lynch Syndrome
“ATLANTA – Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival...
Gilteritinib Improved Survival for Patients With Acute Myeloid Leukemia
“ATLANTA – Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid...
Excess Body Weight Before age 50 is Associated With Higher Risk of Dying From Pancreatic Cancer
ATLANTA – Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess...
Mesothelin-targeted CAR T-cell Therapy Safe, Shows Early Promise in Patients With Advanced Solid Tumors
ATLANTA – A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major...
HER2-targeted CAR T-cell Therapy Safe, With Promising Antitumor Activity in Patients With Advanced Sarcoma
ATLANTA – A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2...